6don MSN
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...
Pfizer Inc. is doubling down on the booming weight-loss drug race, with CEO Albert Bourla declaring the company will be a "formidable competitor" after securing a $10 billion deal to acquire ...
Hosted on MSN
Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition
・Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The company purchased Metsera in November for up to $10 billion to reignite its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results